EyePoint Pharmaceuticals (NASDAQ:EYPT) commercially launched DEXYCU in the U.S. as the first and only FDA-approved intraocular steroid for the treatment of postoperative inflammation.
DEXYCU is administered as a single dose at the end of cataract surgery. It is intended to replace steroid eye drops, which have a dosing regimen that can require self-administration up to four times a day on a titrated schedule for several weeks.
The launch of DEXYCU will be phased, with the initial phase covering cataract surgery experts to ensure proper training on DEXYCU’s administration ahead of its wider availability in the ophthalmology community. The Centers for Medicare and Medicaid Services has assigned a specific and permanent reimbursement J-code for DEXYCU.
DEXYCU is EyePoint’s second ophthalmic product. There are some 4.8 million cataract surgeries a year in the U.S.
